HIV-1--infected individuals produce high titers of antibodies against the virus, but only a small fraction of the patients develop a broadly neutralizing serologic activity, generally after 2--4 yr of infection ([@bib30]; [@bib37]; [@bib39]; [@bib40]; [@bib21]). The serologic anti--HIV-1 activity in some of these individuals can be accounted for by a combination of antibodies targeting different sites on the HIV-1 envelope spike ([@bib32]; [@bib3]; [@bib14]; [@bib10]) and in others, by a predominant highly expanded clone ([@bib33]; [@bib40]; [@bib4]; [@bib21]). Although the presence of broad neutralizing activity does not correlate with a better clinical outcome, passive transfer of broadly neutralizing antibodies (bNAbs) can protect against infection in macaques or in mouse models ([@bib12]; [@bib26]; [@bib21]). In addition, bNAbs can suppress viremia in humanized mice ([@bib15]). Moreover, antibodies against the HIV-1 envelope spike appear to be the unique correlate of protection in the RV144 HIV-1 vaccine trial ([@bib11]). Therefore, it has been proposed that vaccines that would elicit such antibodies may be protective against the infection in humans.

The recent development of efficient methods for cloning of human anti--HIV-1 antibodies from single cells ([@bib32]) led to the discovery of dozens of new bNAbs and new targets for neutralization ([@bib4]; [@bib21]). The new antibodies target at least six different sites of vulnerability on the HIV-1 spike. These include the CD4-binding site (VRC01, NIH45-46, 3BNC60/117, and CH103), the glycan-dependent V1/V2 loops (PG16 and PGT145) and V3 loop (PGT121, PGT128, and the 10-1074 family), a conformational epitope on gp120 (3BC176), a domain in the vicinity of the CD4bs (8ANC195), and the gp41 membrane-proximal external region (MPER; 2F5, 4E10, and 10E8; [@bib32], [@bib33]; [@bib40]; [@bib42]; [@bib16]; [@bib23]; [@bib41]; [@bib18]). Some of these antibodies display remarkable antiviral activity with median 50% inhibitory concentrations (IC50s) \< 0.2 µg/ml for up to 95% of isolates tested ([@bib8]; [@bib33]; [@bib40]; [@bib42]; [@bib4]; [@bib18]).

The antiviral activity of bNAbs is typically measured in vitro using cell-free pseudovirus particles and reporter cell lines, such as the HeLa-derived TzMbl cell ([@bib13]). In these assays, neutralization is mediated by inhibition of free virus binding to cellular receptors and/or by inhibition of viral fusion. Although cell-free HIV-1 is infectious, the virus replicates more efficiently and rapidly through direct contact between cells, and this mode of transmission likely mediates a significant fraction of viral spread and immune evasion in vivo ([@bib7]; [@bib38]; [@bib31]; [@bib24]; [@bib6]). In addition, this form of dissemination appears to be less susceptible to inhibition by antiretroviral drugs than cell-free virus transmission ([@bib5]; [@bib36]; [@bib1]).

Cell to cell spread of HIV-1 is in large part mediated through virological synapses, where viral particles accumulate at the interface between infected cells and targets ([@bib31]; [@bib6]). Synapse formation involves HIV-1 Env-CD4 coreceptor interactions and requires cytoskeletal rearrangements and adhesion molecules ([@bib31]; [@bib6]).

Here, we examined the antiviral activity of a panel of 15 newly identified bNAbs targeting all known sites of vulnerability in conventional neutralization and cell to cell transmission assays. We show that only a subset of the bNAbs that target the CD4-binding site or the glycan/V3 loop efficiently neutralize cell to cell viral transfer in co-cultures of infected T cells with primary lymphocytes. We further characterized the antiviral mechanisms used by the effective antibodies and report that they affect multiple steps of viral cell to cell transfer.

RESULTS AND DISCUSSION
======================

We initially assessed the efficacy of the selected bNAbs to inhibit HIV-1 cell to cell transmission in culture using flow cytometry ([@bib38]). Primary CD4^+^ T cells infected with either NLAD8 or NL4.3 HIV-1 strains were incubated with bNAbs before co-culture with autologous target cells labeled with FarRed. Infection of target cells was measured by Gag expression. In the absence of bNAbs, 15--50% of the recipient cells were Gag^+^ after 48 h (representative experiments are shown in [Fig. 1 a](#fig1){ref-type="fig"}). Under these conditions, the contribution of cell-free virus to infection was negligible because Gag expression by the recipient cells was abrogated by separation of donors and targets in a transwell chamber or when cultures were gently shaken to avoid prolonged contacts ([@bib38]). Moreover, Gag expression in target cells was caused by de novo synthesis because it was significantly reduced in the presence of reverse transcription inhibitor (nevirapine \[NVP\]; [Fig. 1 a](#fig1){ref-type="fig"}).

![**An assay for analyzing inhibition of HIV-1 cell to cell transmission by bNAbs.** (a) bNAbs NIH45-46 and 8ANC195 (15 µg/ml) were incubated for 1 h with primary CD4^+^ T cells infected with HIV-1 (NL4.3 or NLAD8 strains). FarRed-loaded autologous target CD4^+^ T cells were added, and Gag^+^ target cells were measured 48 h later by flow cytometry. One representative experiment (out of four) is shown. The reverse transcription inhibitor NVP was used as a positive control. NI, noninfected cells. (b) Cell-associated inhibition assays were performed as in panel a. bNAbs were used at the indicated doses, and the percentage of inhibition of infection was calculated. For cell-free infections, viruses (NL4.3 or NLAD8 strains) were incubated with the indicated bNAbs for 1 h and then added to HeLa-derived P4C5 target cells, which carry an HIV-1 LTR--β-gal reported cassette. After 36 h, infection was quantified by measuring β-gal activity. Data are mean ± SD from four independent experiments. Lines represent fitted results.](JEM_20131244_Fig1){#fig1}

We tested a panel of 15 bNAbs to investigate their effects on viral cell to cell transmission and in parallel measured their neutralization activity in a conventional cell-free assay ([@bib1]; [@bib13]). As expected, all bNAbs blocked cell-free infection with either NLAD8 or NL4.3, with IC50s varying from 0.05 to 9 µg/ml ([Table 1](#tbl1){ref-type="table"} and [Fig. S1](http://www.jem.org/cgi/content/full/jem.20131244/DC1){#supp1}). However, only a subset efficiently inhibited cell to cell transmission ([Table 1](#tbl1){ref-type="table"} and Fig. S1). Representative inhibition curves with one active (NIH45-46) and one inactive (8ANC195) bNAb are shown in [Fig. 1 b](#fig1){ref-type="fig"}. The most active antibodies in the cell to cell transmission assay were NIH45-46 and 3BNC60, which target the CD4bs, and clonally related anti-glycan/V3 antibodies, 10-1074, 10-996, and PGT121 ([Table 1](#tbl1){ref-type="table"} and Fig. S1; IC50s \< 0.9--2.5 µg/ml). Time of addition experiments showed that NIH45-46 and 3BNC60 remained strongly active when added up to 6 h after the beginning of the co-culture (not depicted). However, the antibody concentrations required to inhibit cell to cell transmission were 10--20-fold higher than cell-free transmission ([Table 1](#tbl1){ref-type="table"} and Fig. S1). As previously reported ([@bib1]), VRC01, a less active clonal relative of NIH45-46, was only partially effective in blocking cell to cell transmission, with 65 and 85% inhibition of NLAD8 and NL4.3, respectively, at concentrations of 15 µg/ml. NIH45-46 and 3BNC60 also inhibited viral spread when CD4^+^ T cells were co-cultured with MOLT cells chronically infected with BaL (not depicted). In contrast, most of the other antibodies tested were relatively ineffective, including the two anti-MPER antibodies and PG16. 10E8 was only partially active against NL43, with 75% inhibition at a concentration of 15 µg/ml, and PG16 showed only 60% inhibition at this concentration.

###### 

Effect of bNAbs on cell-free and cell to cell HIV-1 transmission

  bNAbs       IC50                                                                                                                                      
  ----------- --------------------------------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------------
  NIH45-46    **0.06**                                      *1.2*                                         **0.2**                                       [2.5]{.ul}
  3BNC60      **0.05**                                      *0.9*                                         **0.1**                                       [2.3]{.ul}
  VRC01       **0.2**                                       [7.2]{.ul}[a](#tblfn1){ref-type="table-fn"}   **0.3**                                       **[12.1]{.ul}**[a](#tblfn1){ref-type="table-fn"}
  1NC9        **0.2**                                       [4.5]{.ul}[a](#tblfn1){ref-type="table-fn"}   *0.7*                                         **[12.3]{.ul}**[a](#tblfn1){ref-type="table-fn"}
  12A12       [9.4]{.ul}[a](#tblfn1){ref-type="table-fn"}   X                                             [2.6]{.ul}                                    X
  8ANC195     [4.0]{.ul}[a](#tblfn1){ref-type="table-fn"}   X                                             [5.7]{.ul}[a](#tblfn1){ref-type="table-fn"}   X
  10-1074     X                                             X                                             **0.1**                                       *1.6*
  PGT121      X                                             X                                             **0.1**                                       *1.3*
  10-1074GM   X                                             X                                             **0.3**                                       [6.2]{.ul}
  10-996      X                                             X                                             **0.1**                                       *1.7*
  10-1369     X                                             X                                             **0.4**                                       **[10]{.ul}**[a](#tblfn1){ref-type="table-fn"}
  PG16        *0.7*[a](#tblfn1){ref-type="table-fn"}        \>15                                          **0.05**                                      *0.5*[a](#tblfn1){ref-type="table-fn"}
  3BC176      *0.7*[a](#tblfn1){ref-type="table-fn"}        X                                             \>15                                          X
  10E8        **0.1**                                       [6.7]{.ul}[a](#tblfn1){ref-type="table-fn"}   *1.1*                                         \>15
  4E10        [4.3]{.ul}[a](#tblfn1){ref-type="table-fn"}   X                                             \>15                                          \>15

The indicated antibodies were tested against cell-free and cell-associated HIV-1 infection as indicated in [Fig. 1](#fig1){ref-type="fig"}. Median inhibitory concentrations (IC50) were calculated from at least four independent experiments. The corresponding inhibition curves are displayed [Fig. S1](http://www.jem.org/cgi/content/full/jem.20131244/DC1){#supp2}. Bold indicates IC50 \< 0.5 µg/ml; italics indicate IC50 = 0.5--2 µg/ml; single underline indicates IC50 = 2--10 µg/ml; bold and underline indicate IC50 = 10--15 µg/ml. X, no neutralization (\<25% inhibition at 15 µg/ml).

Partial neutralization (\<90% inhibition at 15 µg/ml).

Some of the bNAbs were also tested for their ability to block cell to cell transmission of two transmitted/founder (T/F) HIV-1 viruses ([@bib29]; [@bib25]). The IC50s of the antibodies against these viruses were generally similar to those observed with NLAD8 ([Table 2](#tbl2){ref-type="table"}). The more active bNAbs against T/F viruses were PG16, 10-1074, and 3BNC60 ([Table 2](#tbl2){ref-type="table"}).

###### 

Antiviral activity of bNAbs on cell to cell transmission of two T/F HIV-1 strains

  bNAbs      IC50                                               
  ---------- -------------------------------------------------- --------------------------------------------------
  NIH45-46   [3.1]{.ul}                                         **[13.9]{.ul}**[a](#tblfn2){ref-type="table-fn"}
  3BNC60     [3.4]{.ul}                                         [3.3]{.ul}
  VRC01      **[14.3]{.ul}**[a](#tblfn2){ref-type="table-fn"}   X
  8ANC195    X                                                  [3.7]{.ul}[a](#tblfn2){ref-type="table-fn"}
  10-1074    *1.8*                                              *1.9*
  PG16       **0.05**                                           **0.3**
  10E8       [9.4]{.ul}[a](#tblfn2){ref-type="table-fn"}        \>15
  3BC176     X                                                  X

Primary HIV-1 CD4^+^ T cells were infected with two T/F HIV-1 strains (WITO or SUMA). Infected cells were preincubated for 1 h with different doses of bNAbs before co-culture with autologous target cells stained with FarRed dye. After 48 h, the fraction of productively infected (Gag^+^) target cells was measured by flow cytometry. The median inhibitory concentrations (IC50) were calculated with cells from three to four independent donors. Bold indicates IC50 \< 0.5 µg/ml; italics indicate IC50 = 0.5--2 µg/ml; single underline indicates IC50 = 2--10 µg/ml; bold and underline indicate IC50 = 10--15 µg/ml. X, no neutralization (\<25% inhibition at 15 µg/ml).

Partial neutralization (\<90% inhibition at 15 µg/ml).

The first step in cell to cell spread is the formation of conjugates between infected cells and targets, a process which is dependent on Env ([@bib20]). To examine the mechanism of inhibition of cell to cell transmission by bNAbs, we initially assayed their effects on conjugate formation. Preincubation of NL4.3- or BaL-infected lymphocytes with NIH45-46, 3BNC60, or VRC01 decreased the formation of conjugates, and 10-1074 and PGT121 inhibited the formation of clusters with cells expressing HIV-BaL ([Fig. 2, a and b](#fig2){ref-type="fig"}). In contrast, the other bNAbs did not show measurable inhibitory effects ([Fig. 2, a and b](#fig2){ref-type="fig"}). Of note, 10E8 increased formation of conjugates with NL4.3 and was ineffective against BaL ([Fig. 2, a and b](#fig2){ref-type="fig"}). It is possible that 10E8, which blocks Env-mediated fusion without affecting Env-CD4 interaction, may stabilize cell conjugates in the absence of cell fusion.

![**Effect of bNAbs on formation of conjugates of infected and target cells.** (a) CFSE-stained MOLT cells chronically infected with HIV-1 NL4.3 or BaL strains were preincubated for 1 h with 15 µg/ml NIH45-46 bNAb and then co-cultured with FarRed-stained primary CD4^+^ T cells. After 2 h, conjugates of donors and targets (CFSE^+^FarRed^+^) were quantified by flow cytometry. (left) Flow plots from one representative experiment are shown. (right) Frequency of conjugates with noninfected (NI) and NL4.3- or BaL-infected MOLT cells in the absence of bNAb. Each dot represents an experiment with primary target T cells from independent donors. The bars represent SD. \*, P \< 0.05. (b) Conjugate formation in the presence of the indicated bNAbs (15 µg/ml) as determined in panel a. Data are shown from six independent experiments. The percentage of cell-forming conjugates is shown. \*, P \< 0.05 (Wilcoxon matched pairs test). (c) HeLa cells stably expressing HIV-1 Env (NL4.3) and Tat were preincubated for 1 h with the indicated bNAbs (15 µg/ml) before overnight co-culture with HeLa P4C5 cells, which carry an HIV-1 LTR--β-gal reporter cassette. Upon syncytia formation, Tat will transactivate the HIV-1 LTR. Levels of syncytia were quantified by measuring β-gal activity. Data represent mean ± SD of triplicate samples from six independent experiments. \*, P \< 0.05.](JEM_20131244_Fig2){#fig2}

Contact between Env^+^ cells and target cells can lead to formation of syncytia. Therefore, we assessed the effect of bNAbs on syncytia formation using a quantitative assay, in which HeLa cells expressing Env (from NL4.3) and Tat are mixed with HeLa cells expressing CD4 and HIV-1 LTR--β-gal reporter cassette (P4C5 cells; [@bib34]). β-gal expression is induced upon fusion and transfer of Tat between the two cell types. NIH45-46, 3BNC60, and VRC01 blocked fusion as did the anti-gp41 MPER 10E8 ([Fig. 2 c](#fig2){ref-type="fig"}). In contrast, bNAbs that failed to inhibit cell to cell transmission of NL4.3 had little or no effect on fusion ([Fig. 2 c](#fig2){ref-type="fig"}).

After formation of cell conjugates, viral particles are transferred from infected cells to targets. To measure viral transfer, we examined Gag expression in target cells by flow cytometry. 4 h after initiation of the co-culture, 4--6% of target cells were Gag^+^ ([Fig. 3 a](#fig3){ref-type="fig"}). NIH45-46, 3BNC60, VRC01, and 10-1074 decreased transfer of NL4.3 and/or NLAD8, whereas the other antibodies were inactive ([Fig. 3 a](#fig3){ref-type="fig"}). Immunofluorescence and confocal imaging further demonstrated that preincubation of donor cells with NIH45-46 or 3BNC60 led to accumulation of the bNAb at the virological synapse and to colocalization with Gag ([Fig. 3 b](#fig3){ref-type="fig"}). Moreover, an examination of target cells that captured viral particles despite the presence of bNAbs demonstrated that these viruses were generally, if not always, coated with bNAbs ([Fig. 3 c](#fig3){ref-type="fig"}).

![**Effect of bNAbs on HIV-1 capture by target cells.** (a) Primary HIV-1--infected CD4^+^ T cells (NL4.3 or NLAD8 strains) were preincubated for 1 h with the indicated bNAbs (15 µg/ml) before co-culture with autologous target cells stained with FarRed. After 4 h, the fraction of target cells having captured viral material (Gag^+^) was measured by flow cytometry. Data are mean ± SD of six independent experiments. \*, P \< 0.05. (b) FarRed^+^ HIV-1--infected CD4^+^ T cells or Jurkat cells were preincubated for 1 h with the indicated bNAbs before a 1.5-h co-culture with target cells stained with CFSE. Cells were stained with anti-Gag mAbs and with a secondary anti--human antibody (yellow) to visualize the bNAb. Examples of virological synapses in primary CD4^+^ T cells (top) and in Jurkat cells (bottom) are shown. D, donor cell; T, target cell. (c) The co-cultures of primary CD4^+^ T cells described in b were analyzed for target cells that were not or no longer in contact with donor cells. Images are representative of three independent experiments. Bars, 5 µm.](JEM_20131244_Fig3){#fig3}

Plasmacytoid DC (pDCs) sense HIV-1--infected cells and react by producing type-I IFN ([@bib17]). To determine whether bNAbs inhibit the recognition of infected lymphocytes by pDCs, infected donor cells were preincubated with bNAbs and co-cultured with target PBMCs. The levels of type-I IFN were measured in supernatants after 18 h of co-culture. NIH45-46, 3BNC60, VRC01, and 10-1074 inhibited IFN induction by lymphocytes infected with NL4.3 and/or NLAD8, whereas PG16 and 10E8 were inactive ([Fig. 4 a](#fig4){ref-type="fig"}). In addition, the role of antibodies in blocking transmission was examined using the pDC-like cell line Gen2.2 as target cells ([@bib17]). NIH45-46, 3BNC60, VRC01, 10-1074, PG16, and 10E8 blocked HIV-1 infection of Gen2.2 cells ([Fig. 4 b](#fig4){ref-type="fig"}). Moreover, bNAbs that blocked Gen2.2 infection also inhibited induction of the IFN-induced protein MxA. Thus, in addition to inhibiting lymphocyte to lymphocyte viral spread, the most active bNAbs block transmission from lymphocytes to pDCs and impair innate immune sensing of the virus.

![**Effect of bNAbs on HIV-1 sensing by hematopoietic cells.** (a) HIV-1--infected MT4C5 lymphoblastoid T cells were incubated for 1 h with the indicated bNAbs (15 µg/ml) and used as donors. Target cells were PBMCs, and levels of type-I IFN released in supernatants were measured 18 h later. NI, co-culture with noninfected cells. Data are mean ± SD of at least three independent experiments. \*, P \< 0.05. (b and c) HIV-infected MT4C5 cells were incubated with the indicated bNAbs for 1 h before mixing with Gen2.2 cells. After 48 h, the levels of cells productively infected (Gag^+^; b) or expressing the IFN-stimulated protein MxA (c) were measured by flow cytometry. Data are mean ± SD of at least three independent experiments. \*, P \< 0.05.](JEM_20131244_Fig4){#fig4}

To date, only VRC01 among the second generation, more potent, bNAbs has been assayed for its ability to block HIV-1 cell to cell transmission, and in agreement with our own findings, it was reported to be poorly active ([@bib5]; [@bib20]; [@bib19]; [@bib1]). Here, we show that many of the 15 bNAbs tested, including some of the most active antibodies to six different sites of vulnerability on the envelope, were ineffective in HIV-1 cell to cell transmission. However, five bNAbs, isolated from four different patients (NIH45-46, 3BNC60, PGT121, 10-1074, and PG16) blocked the intercellular spread of the tested viruses at IC50s of 0.05--2.5 µg/ml. NIH45-46 and 3BNC60 target the CD4-binding site, whereas 10-1074 and PGT121 bind to a complex epitope composed of glycans and the V3 loop epitope on HIV-1 gp120 ([@bib32]; [@bib40]; [@bib42]; [@bib16]; [@bib23]; [@bib18]). Of note, 10-1074 and PGT121 efficiently inhibited cell-free and cell to cell transmission of all R5 viruses tested but were inactive against the X4 strain NL4.3. Further work will help determining whether V3-directed bNAbs inhibit other X4 isolates.

The bNAbs inhibiting cell to cell viral spread were those acting at a low concentration against free virus (IC50 \< 0.2 µg/ml; [@bib33]; [@bib40]). This suggests that very high levels of potency in cell-free virion assays are required for antibodies to block viral cell--cell spread. But potency alone may not be sufficient, as indicated by 10E8, which fails to reach 80% neutralizing activity in cell to cell transmission despite potencies that are nearly comparable with the effective antibodies in cell-free assays. It is noteworthy that the concentrations required to inhibit cell to cell transmission were at least 10--20-fold higher than for free virus. Similarly, the serum concentrations of bNAbs required to inhibit infection in mouse or monkey models of HIV-1 infection are also 1--2 logs higher than in cell-free assays ([@bib2]; [@bib14]; [@bib22]; [@bib26]). Cell to cell transmission may therefore provide a more reliable method for predicting the potency of bNAbs in vivo.

Our experiments show that the most active bNAbs interfere with cell to cell transmission by efficiently impairing formation of clusters between infected cells and targets, the appearance of syncytia, and transfer of viral material to recipient cells and by accumulating at the virological synapse. Moreover, they also decorate any free viral particles that may still have been captured by target cells. Additional experimentation will be required to determine whether the various bNAbs display differing abilities to accumulate at sites of cell--cell contacts and to impair the formation of virological synapses. It will also be of interest to further examine how these bNAbs interfere with viral cell to cell transmission between myeloid DCs and lymphocytes.

HIV-1 cell to cell transmission is likely playing a predominant role in infected individuals ([@bib24]). Our results confirm that this mode of viral spread may represent a means to escape the selection pressure exerted by most of the bNAbs ([@bib9]; [@bib1]). Our observations may also help explain why some bNAbs like 3BC176 are ineffective in vivo ([@bib15]), whereas others like 10-1074 and a derivative of NIH45-46 (45-46W) suppressed viral loads below detection ([@bib15]). Consistent with this idea, 10E8, which does not efficiently inhibit HIV-1 cell to cell transmission, failed to suppress viremia in vivo and failed to select antibody-resistant HIV-1 variants ([Fig. S2](http://www.jem.org/cgi/content/full/jem.20131244/DC1){#supp3}). We speculate that bNAbs that effectively interfere with cell to cell transmission in vitro will also display efficient and long-lasting therapeutic or prophylactic properties in vivo.

MATERIALS AND METHODS
=====================

### Cells and viruses.

MOLT cells chronically infected with NL4.3 or BaL isolates and MT4C5 cells were grown as described previously ([@bib20]; [@bib28]). Primary CD4^+^ T cells were purified from human peripheral blood by positive selection (Miltenyi Biotec). About 98% of cells were CD4^+^CD3^+^. For activation, primary T cells were treated with 1 µg/ml PHA for 24 h and then cultured with 50 IU/ml IL-2 for 3--5 d before use. NL4.3, NLAD8, and T/F HIV-1 strains WITO and SUMA ([@bib25]) were obtained through the National Institutes of Health AIDS reagents program and prepared by transfection of 293T cells ([@bib28]). Primary cells were infected with HIV-1 as described previously ([@bib17]). HIV-1 strains used are R5, except NL4.3 (X4). The *env* genes correspond to viruses with high (tier 1 for NL4.3 and BaL) or moderate (tier 2 for WITO) sensitivity to antibody-mediated neutralization ([@bib35]).

### bNAbs.

bNAbs were prepared as described previously ([@bib32]; [@bib23]).

### Viral cell to cell transmission assay.

Donor cells were infected with the indicated HIV-1 strains and used a few days later, when ∼10--75% of the cells were Gag^+^. Target cells were labeled with FarRed or 2.5 µM CFSE (Molecular Probes). Donors were preincubated with the indicated doses of bNAbs. Donor and target cells were then mixed at a 1:2 ratio in 96-well plates at a final concentration of 1.5 × 10^6^/ml in 200 µl. After 48 h, cells were stained for intracellular Gag (KC57 mAb; Beckman Coulter) and analyzed by flow cytometry. When stated, 12.5 nM NVP was added 1 h before co-culture.

### Cell-free infection of P4C5 cells.

The neutralization activity of bNAbs was evaluated on P4C5 cells (HeLa CD4^+^CCR5^+^ cells carrying an HIV-1 LTR--β-gal reporter cassette). 1 d before infection, 7 × 10^3^ cells were plated in 96-well plates. Cells were infected in triplicate with 1 or 5 ng Gag p24. Viruses were incubated with the indicated bNAbs for 1 h before infection. After 36 h, cells were lysed in PBS, 0.1% NP-40, and 5 mM MgCl~2~ and incubated with the β-gal substrate CPRG (Roche), before measurement of 570-nm OD.

### Calculation of IC50.

Dose--response inhibition curves were drawn by fitting data from three to six independent experiments to sigmoid dose--response curves (variable slope) using Prism software (GraphPad Software). Percentage of inhibition was defined as (percent signal in nontreated target cells − percent signal in bNAb-treated cells)/(percent signal in nontreated target cells) × 100. The IC50 was calculated with Prism.

### Analysis of conjugate formation between infected and target cells.

Chronically infected MOLT cells (2 × 10^5^/well) were stained with CFSE and preincubated in 96-well plates with 15 µg/ml bNAbs for 1 h at 37°C, before adding 2 × 10^5^ FarRed-labeled CD4 T cells for 2 h ([@bib20]). Cellular contacts were measured by flow cytometry. CFSE^+^FarRed^+^ cells were considered as cellular conjugates. The percentage of conjugates was calculated as follows: (conjugates/total conjugates + MOLT cells + CD4 T cells) × 100.

### Analysis of HIV-1 capture by target cells.

Primary donor cells were infected with HIV-1 and used a few days later, when 10--75% of the cells were Gag^+^. The indicated target cells were labeled with FarRed or 2.5 µM CFSE (Molecular Probes). Donors were incubated with bNAbs for 1 h. Donor and target cells were then mixed at a 1:2 ratio in 96-well plates at a final concentration of 1.5 × 10^6^/ml in 200 µl. After 4 h, target cells were stained for Gag and analyzed by flow cytometry.

### Syncytia assay.

HeLa 243 cells, which stably express the HIV-1 NL4.3 Env and Tat proteins ([@bib34]), seeded at 8 × 10^3^ cells in 96-well plates, were preincubated for 1 h with 15 µg/ml bNAbs, before addition of 8 × 10^3^ P4C5 cells for 8 h. Upon cell fusion, Tat transactivates the HIV-1 LTR and drives expression of β-gal, at levels which correlate with the amount of syncytia ([@bib34]).

### Immunofluorescence analysis.

HIV-infected primary donor CD4^+^ T cells were treated with the indicated bNAbs for 1 h before addition of autologous targets. After 1 h of co-culture, cells were fixed and double Gag/bNAb stainings were performed with a mouse mAb anti-p24 and a secondary anti--human antibody to visualize the bNAb. Confocal microscopy analysis was performed on an LSM700 (Carl Zeiss) using a 40 or 63 objective. Z-series of optical sections were performed at 0.2--0.5-µm increments.

### Sensing of HIV-infected cells by hematopoietic cells.

The indicated infected donor cells were incubated for 1 h with the bNAb and mixed with target cells (PBMCs or Gen2.2) at a ratio of 1:2 in 96-well plates at a final concentration of 2--3 × 10^6^/ml in 100 µl for PBMCs, or 10^6^/ml in 200 µl for Gen2.2, as described previously ([@bib17]). After a co-culture of 18 h (PBMCs) or 48 h (Gen2.2), type I IFN levels and expression of the protein MxA were measured as described previously ([@bib17]; [@bib27]).

### Infection of humanized mice.

HIV-1 infection of humanized mice, bNAb treatments, and analysis of viral loads and sequences were performed as described previously ([@bib15]). Animal experiments were performed with authorization from the Institutional Review Board and the Institutional Animal Care and Use Committee at the Rockefeller University.

### Statistical analyses.

Wilcoxon-matched paired Student's *t* tests (and Mann--Whitney unpaired Student's *t* test in [Fig. 3 b](#fig3){ref-type="fig"}) were performed using Prism software.

### Online supplemental material.

Fig. S1 shows dose--response analysis of the antiviral effect of bNAb on cell-free and cell-associated infections. Fig. S2 shows that 10E8 treatment does not impose selective pressure on HIV-1 infection in humanized mice. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20131244/DC1>.
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